دورية أكاديمية
أعرض في EDS

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.

التفاصيل البيبلوغرافية
العنوان: CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.
المؤلفون: Walls GM; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland, UK., Oughton JB; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK., Chalmers AJ; Institute of Cancer Sciences, University of Glasgow, Scotland, UK., Brown S; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK., Collinson F; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK., Forster MD; Department of Oncology, UCL Cancer Institute, England, UK., Franks KN; St James' Institute of Oncology, University of Leeds, England, UK., Gilbert A; St James' Institute of Oncology, University of Leeds, England, UK., Hanna GG; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia., Hannaway N; Newcastle University, Newcastle upon Tyne, England, UK., Harrow S; The Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK., Haswell T; Patient and Public Involvement Advocacy, UK., Hiley CT; Department of Oncology, UCL Cancer Institute, England, UK., Hinsley S; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.; Institute of Cancer Sciences, University of Glasgow, Scotland, UK., Krebs M; Faculty of Biology, Medicine and Health, University of Manchester, England, UK., Murden G; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK., Phillip R; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK., Ryan AJ; Oxford Institute for Radiation Oncology, University of Oxford, Oxford, England, UK., Salem A; The Christie NHS Foundation Trust/University of Manchester, Manchester, England, UK., Sebag-Montefoire D; St James' Institute of Oncology, University of Leeds, England, UK., Shaw P; Velindre University NHS Trust, Cardiff, Wales, UK., Twelves CJ; St James' Institute of Oncology, University of Leeds, England, UK., Walker K; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK., Young RJ; Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, England, UK., Faivre-Finn C; Oxford Institute for Radiation Oncology, University of Oxford, Oxford, England, UK., Greystoke A; Newcastle University, Newcastle upon Tyne, England, UK.
المصدر: Clinical and translational radiation oncology [Clin Transl Radiat Oncol] 2020 Sep 22; Vol. 25, pp. 61-66. Date of Electronic Publication: 2020 Sep 22 (Print Publication: 2020).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Ireland Ltd. on behalf of European Society for Radiotherapy and Oncology Country of Publication: Ireland NLM ID: 101713416 Publication Model: eCollection Cited Medium: Internet ISSN: 2405-6308 (Electronic) Linking ISSN: 24056308 NLM ISO Abbreviation: Clin Transl Radiat Oncol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Shannon] : Elsevier Ireland Ltd. on behalf of European Society for Radiotherapy and Oncology, [2016]-
مستخلص: Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.)
References: Clin Oncol (R Coll Radiol). 2020 Jun;32(6):358-362. (PMID: 32107107)
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. (PMID: 8433390)
Radiother Oncol. 2013 Oct;109(1):8-12. (PMID: 24094626)
Signal Transduct Target Ther. 2020 May 1;5(1):60. (PMID: 32355263)
Stat Med. 2003 Jul 30;22(14):2239-56. (PMID: 12854091)
Clin Oncol (R Coll Radiol). 2016 Nov;28(11):720-725. (PMID: 27591000)
Ann Oncol. 2009 Jan;20(1):98-102. (PMID: 18718891)
Biometrics. 2000 Dec;56(4):1177-82. (PMID: 11129476)
N Engl J Med. 2017 Aug 10;377(6):523-533. (PMID: 28578601)
N Engl J Med. 2020 May 28;382(22):2091-2102. (PMID: 32343890)
Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):487-9. (PMID: 25304944)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Clin Transl Radiat Oncol. 2017 Nov 21;8:12-16. (PMID: 29594237)
Am J Clin Oncol. 1982 Dec;5(6):649-55. (PMID: 7165009)
Br J Cancer. 2016 May 24;114(11):1199-205. (PMID: 27140316)
Mol Cancer Res. 2018 Feb;16(2):222-232. (PMID: 29133592)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Clin Oncol (R Coll Radiol). 2019 Oct;31(10):688-696. (PMID: 31514942)
Front Oncol. 2019 Oct 10;9:1009. (PMID: 31649878)
Lancet Oncol. 2010 May;11(5):459-64. (PMID: 20378407)
Clin Cancer Res. 2015 Jul 1;21(13):2898-904. (PMID: 26133775)
Br J Radiol. 2016;89(1060):20150431. (PMID: 26838950)
J Thorac Cardiovasc Surg. 2018 Jan;155(1):356-359. (PMID: 29061464)
Nat Rev Clin Oncol. 2016 Oct;13(10):627-42. (PMID: 27245279)
N Engl J Med. 2020 Feb 6;382(6):503-513. (PMID: 31995683)
Ann Oncol. 2017 Nov 01;28(11):2874-2881. (PMID: 28945875)
Clin Chest Med. 2011 Dec;32(4):605-44. (PMID: 22054876)
Radiother Oncol. 2017 Sep;124(3):475-481. (PMID: 28697853)
N Engl J Med. 2018 Dec 13;379(24):2342-2350. (PMID: 30280658)
Eur J Gynaecol Oncol. 2010;31(4):386-91. (PMID: 20882878)
Lung Cancer. 2001 Apr;32(1):27-38. (PMID: 11282426)
BMJ Open. 2016 Apr 15;6(4):e010457. (PMID: 27084277)
Radiat Oncol. 2017 Dec 29;12(1):208. (PMID: 29287602)
Gynecol Oncol. 2017 Mar;144(3):486-490. (PMID: 28109627)
Cancer Treat Res Commun. 2018;16:9-12. (PMID: 31299005)
J Clin Oncol. 2010 May 1;28(13):2181-90. (PMID: 20351327)
J Clin Oncol. 2016 Dec 20;34(36):4371-4380. (PMID: 27601554)
J Clin Oncol. 2020 Mar 1;38(7):706-714. (PMID: 31841363)
Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):733-742. (PMID: 31809876)
Clin Cancer Res. 2019 Mar 1;25(5):1455-1461. (PMID: 30498095)
Radiother Oncol. 2014 May;111(2):228-36. (PMID: 24857596)
Clin Cancer Res. 2018 Oct 15;24(20):4949-4959. (PMID: 30084837)
Br J Cancer. 2016 Oct 25;115(9):1147-1155. (PMID: 27727232)
Lancet Oncol. 2017 Sep;18(9):1274-1284. (PMID: 28754483)
Radiother Oncol. 2004 May;71(2):139-46. (PMID: 15110446)
N Engl J Med. 2006 Feb 9;354(6):567-78. (PMID: 16467544)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
Radiother Oncol. 2010 Apr;95(1):32-40. (PMID: 19733410)
معلومات مُعتمدة: 28890 United Kingdom CRUK_ Cancer Research UK; 17870 United Kingdom CRUK_ Cancer Research UK; G0802755 United Kingdom MRC_ Medical Research Council; 28803 United Kingdom CRUK_ Cancer Research UK; MC_UU_00001/6 United Kingdom MRC_ Medical Research Council; MC_PC_12006 United Kingdom MRC_ Medical Research Council; 28990 United Kingdom CRUK_ Cancer Research UK; G108/589 United Kingdom MRC_ Medical Research Council; 25447 United Kingdom CRUK_ Cancer Research UK; 20546 United Kingdom CRUK_ Cancer Research UK; 28301 United Kingdom CRUK_ Cancer Research UK
فهرسة مساهمة: Keywords: ATM, Ataxia telangiectasia mutated; ATR, Ataxia telangiectasia and Rad3 related; CRT, Chemoradiotherapy; CT, Computed tomography; CTCAE, Common terminology criteria for adverse events; CTRad, Clinical and Translational Radiotherapy Research Working Group; Continual reassessment method; DDRi, DNA damage response inhibitor; DLT, Dose limiting toxicity; DNA damage repair inhibitor; DNA, Deoxyribonucleic acid; DNA-PK, DNA-dependent protein kinase; ECOG, Eastern Cooperative Oncology Group; EORTC, European Organisation for Research and Treatment of Cancer; ICRU, International Commission on Radiation Units and Measurements; IMPs, Investigational medicinal products; LA, Locally advanced; MRC, Medical Research Council; NCRI, National Cancer Research Institute; NSCLC, Non-small cell lung cancer; Non-small cell lung cancer; PARP, Poly (ADP-ribose) polymerase; PET, Positron emission tomography; PFS, Progression free survival; PROMs, Patient-reported outcome measures; Platform trial; RECIST, Response evaluation criteria in solid tumours; RP2D, Recommended phase II dose; RT, Radiotherapy; SACT, Systemic anti-cancer therapy; SRC, Safety review committee; Sequential chemoradiotherapy; TNM, Tumour node metastasis; TiTE-CRM, Time to event continual reassessment method; cfDNA, Cell-free DNA
تواريخ الأحداث: Date Created: 20201019 Latest Revision: 20240210
رمز التحديث: 20240210
مُعرف محوري في PubMed: PMC7548952
DOI: 10.1016/j.ctro.2020.09.006
PMID: 33072895
قاعدة البيانات: MEDLINE
الوصف
تدمد:2405-6308
DOI:10.1016/j.ctro.2020.09.006